Bridgebio Pharma Stock Volatility
| BBIO Stock | USD 27.49 1.05 3.97% |
BridgeBio Pharma appears to be not too volatile, given 3 months investment horizon. BridgeBio Pharma secures Sharpe Ratio (or Efficiency) of 0.062, which signifies that the company had a 0.062% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for BridgeBio Pharma, which you can use to evaluate the volatility of the firm. Please makes use of BridgeBio Pharma's Downside Deviation of 2.9, risk adjusted performance of 0.0284, and Mean Deviation of 2.72 to double-check if our risk estimates are consistent with your expectations. Key indicators related to BridgeBio Pharma's volatility include:
30 Days Market Risk | Chance Of Distress | 30 Days Economic Sensitivity |
BridgeBio Pharma Stock volatility depicts how high the prices fluctuate around the mean (or its average) price. In other words, it is a statistical measure of the distribution of BridgeBio daily returns, and it is calculated using variance and standard deviation. We also use BridgeBio's beta, its sensitivity to the market, as well as its odds of financial distress to provide a more practical estimation of BridgeBio Pharma volatility.
BridgeBio |
ESG Sustainability
While most ESG disclosures are voluntary, BridgeBio Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BridgeBio Pharma's managers and investors.Environmental | Governance | Social |
Since volatility provides investors with entry points to take advantage of stock prices, companies, such as BridgeBio Pharma can benefit from it. Downward market volatility can be a perfect environment for investors who play the long game. Here, they may decide to buy additional stocks of BridgeBio Pharma at lower prices. For example, an investor can purchase BridgeBio stock that has halved in price over a short period. This will lower your average cost per share, thereby improving your portfolio's performance when the markets normalize. Similarly, when the prices of BridgeBio Pharma's stock rises, investors can sell out and invest the proceeds in other equities with better opportunities. Investing when markets are volatile with better valuations will accord both investors and companies the opportunity to generate better long-term returns.
Moving against BridgeBio Stock
| 0.5 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.37 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.34 | OPT | Opthea | PairCorr |
BridgeBio Pharma Market Sensitivity And Downside Risk
BridgeBio Pharma's beta coefficient measures the volatility of BridgeBio stock compared to the systematic risk of the entire market represented by your selected benchmark. In mathematical terms, beta represents the slope of the line through a regression of data points where each of these points represents BridgeBio stock's returns against your selected market. In other words, BridgeBio Pharma's beta of 1.25 provides an investor with an approximation of how much risk BridgeBio Pharma stock can potentially add to one of your existing portfolios. BridgeBio Pharma currently demonstrates below-average downside deviation. It has Information Ratio of -0.01 and Jensen Alpha of -0.06. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure BridgeBio Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact BridgeBio Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.
3 Months Beta |Analyze BridgeBio Pharma Demand TrendCheck current 90 days BridgeBio Pharma correlation with market (Dow Jones Industrial)BridgeBio Beta |
BridgeBio standard deviation measures the daily dispersion of prices over your selected time horizon relative to its mean. A typical volatile entity has a high standard deviation, while the deviation of a stable instrument is usually low. As a downside, the standard deviation calculates all uncertainty as risk, even when it is in your favor, such as above-average returns.
Standard Deviation | 4.01 |
It is essential to understand the difference between upside risk (as represented by BridgeBio Pharma's standard deviation) and the downside risk, which can be measured by semi-deviation or downside deviation of BridgeBio Pharma's daily returns or price. Since the actual investment returns on holding a position in bridgebio stock tend to have a non-normal distribution, there will be different probabilities for losses than for gains. The likelihood of losses is reflected in the downside risk of an investment in BridgeBio Pharma.
BridgeBio Pharma Stock Volatility Analysis
Volatility refers to the frequency at which BridgeBio Pharma stock price increases or decreases within a specified period. These fluctuations usually indicate the level of risk that's associated with BridgeBio Pharma's price changes. Investors will then calculate the volatility of BridgeBio Pharma's stock to predict their future moves. A stock that has erratic price changes quickly hits new highs, and lows are considered highly volatile. A stock with relatively stable price changes has low volatility. A highly volatile stock is riskier, but the risk cuts both ways. Investing in highly volatile security can either be highly successful, or you may experience significant failure. There are two main types of BridgeBio Pharma's volatility:
Historical Volatility
This type of stock volatility measures BridgeBio Pharma's fluctuations based on previous trends. It's commonly used to predict BridgeBio Pharma's future behavior based on its past. However, it cannot conclusively determine the future direction of the stock.Implied Volatility
This type of volatility provides a positive outlook on future price fluctuations for BridgeBio Pharma's current market price. This means that the stock will return to its initially predicted market price. This type of volatility can be derived from derivative instruments written on BridgeBio Pharma's to be redeemed at a future date.Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. BridgeBio Pharma Average Price is the average of the sum of open, high, low and close daily prices of a bar. It can be used to smooth an indicator that normally takes just the closing price as input.
BridgeBio Pharma Projected Return Density Against Market
Given the investment horizon of 90 days the stock has the beta coefficient of 1.2508 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, BridgeBio Pharma will likely underperform.Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to BridgeBio Pharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that BridgeBio Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a BridgeBio stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
BridgeBio Pharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Predicted Return Density |
| Returns |
What Drives a BridgeBio Pharma Price Volatility?
Several factors can influence a stock's market volatility:Industry
Specific events can influence volatility within a particular industry. For instance, a significant weather upheaval in a crucial oil-production site may cause oil prices to increase in the oil sector. The direct result will be the rise in the stock price of oil distribution companies. Similarly, any government regulation in a specific industry could negatively influence stock prices due to increased regulations on compliance that may impact the company's future earnings and growth.Political and Economic environment
When governments make significant decisions regarding trade agreements, policies, and legislation regarding specific industries, they will influence stock prices. Everything from speeches to elections may influence investors, who can directly influence the stock prices in any particular industry. The prevailing economic situation also plays a significant role in stock prices. When the economy is doing well, investors will have a positive reaction and hence, better stock prices and vice versa.The Company's Performance
Sometimes volatility will only affect an individual company. For example, a revolutionary product launch or strong earnings report may attract many investors to purchase the company. This positive attention will raise the company's stock price. In contrast, product recalls and data breaches may negatively influence a company's stock prices.BridgeBio Pharma Stock Risk Measures
Given the investment horizon of 90 days the coefficient of variation of BridgeBio Pharma is 1612.62. The daily returns are distributed with a variance of 16.05 and standard deviation of 4.01. The mean deviation of BridgeBio Pharma is currently at 2.81. For similar time horizon, the selected benchmark (Dow Jones Industrial) has volatility of 0.76
α | Alpha over Dow Jones | -0.06 | |
β | Beta against Dow Jones | 1.25 | |
σ | Overall volatility | 4.01 | |
Ir | Information ratio | -0.0064 |
BridgeBio Pharma Stock Return Volatility
BridgeBio Pharma historical daily return volatility represents how much of BridgeBio Pharma stock's daily returns swing around its mean - it is a statistical measure of its dispersion of returns. The firm inherits 4.0063% risk (volatility on return distribution) over the 90 days horizon. By contrast, Dow Jones Industrial accepts 0.7734% volatility on return distribution over the 90 days horizon. Performance |
| Timeline |
About BridgeBio Pharma Volatility
Volatility is a rate at which the price of BridgeBio Pharma or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of BridgeBio Pharma may increase or decrease. In other words, similar to BridgeBio's beta indicator, it measures the risk of BridgeBio Pharma and helps estimate the fluctuations that may happen in a short period of time. So if prices of BridgeBio Pharma fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility.
Please read more on our technical analysis page.| Last Reported | Projected for Next Year | ||
| Market Cap | 6.6 B | 6.9 B |
BridgeBio Pharma's stock volatility refers to the amount of uncertainty or risk involved with the size of changes in its stock's price. It is a statistical measure of the dispersion of returns on BridgeBio Stock over a specified period of time, often expressed as the standard deviation of daily returns. In other words, it measures how much BridgeBio Pharma's price varies over time.
3 ways to utilize BridgeBio Pharma's volatility to invest better
Higher BridgeBio Pharma's stock volatility means that the price of its stock is changing rapidly and unpredictably, while lower stock volatility indicates that the price of BridgeBio Pharma stock is relatively stable. Investors and traders use stock volatility as an indicator of risk and potential reward, as stocks with higher volatility can offer the potential for more significant returns but also come with a greater risk of losses. BridgeBio Pharma stock volatility can provide helpful information for making investment decisions in the following ways:- Measuring Risk: Volatility can be used as a measure of risk, which can help you determine the potential fluctuations in the value of BridgeBio Pharma investment. A higher volatility means higher risk and potentially larger changes in value.
- Identifying Opportunities: High volatility in BridgeBio Pharma's stock can indicate that there is potential for significant price movements, either up or down, which could present investment opportunities.
- Diversification: Understanding how the volatility of BridgeBio Pharma's stock relates to your other investments can help you create a well-diversified portfolio of assets with varying levels of risk.
BridgeBio Pharma Investment Opportunity
BridgeBio Pharma has a volatility of 4.01 and is 5.21 times more volatile than Dow Jones Industrial. 35 percent of all equities and portfolios are less risky than BridgeBio Pharma. You can use BridgeBio Pharma to enhance the returns of your portfolios. The stock experiences an unexpected upward trend. Watch out for market signals. Check odds of BridgeBio Pharma to be traded at $32.99 in 90 days.Modest diversification
The correlation between BridgeBio Pharma and DJI is 0.24 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding BridgeBio Pharma and DJI in the same portfolio, assuming nothing else is changed.
BridgeBio Pharma Additional Risk Indicators
The analysis of BridgeBio Pharma's secondary risk indicators is one of the essential steps in making a buy or sell decision. The process involves identifying the amount of risk involved in BridgeBio Pharma's investment and either accepting that risk or mitigating it. Along with some common measures of BridgeBio Pharma stock's risk such as standard deviation, beta, or value at risk, we also provide a set of secondary indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Risk Adjusted Performance | 0.0284 | |||
| Market Risk Adjusted Performance | 0.086 | |||
| Mean Deviation | 2.72 | |||
| Semi Deviation | 2.76 | |||
| Downside Deviation | 2.9 | |||
| Coefficient Of Variation | 3758.27 | |||
| Standard Deviation | 3.95 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential stocks, we recommend comparing similar stocks with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
BridgeBio Pharma Suggested Diversification Pairs
Pair trading is one of the very effective strategies used by professional day traders and hedge funds capitalizing on short-time and mid-term market inefficiencies. The approach is based on the fact that the ratio of prices of two correlating shares is long-term stable and oscillates around the average value. If the correlation ratio comes outside the common area, you can speculate with a high success rate that the ratio will return to the mean value and collect a profit.
The effect of pair diversification on risk is to reduce it, but we should note this doesn't apply to all risk types. When we trade pairs against BridgeBio Pharma as a counterpart, there is always some inherent risk that will never be diversified away no matter what. This volatility limits the effect of tactical diversification using pair trading. BridgeBio Pharma's systematic risk is the inherent uncertainty of the entire market, and therefore cannot be mitigated even by pair-trading it against the equity that is not highly correlated to it. On the other hand, BridgeBio Pharma's unsystematic risk describes the types of risk that we can protect against, at least to some degree, by selecting a matching pair that is not perfectly correlated to BridgeBio Pharma.
When determining whether BridgeBio Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BridgeBio Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bridgebio Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bridgebio Pharma Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.